Links for Keyword: Drug Abuse

Follow us on Facebook and Twitter, or subscribe to our mailing list, to receive news updates. Learn more.


Links 1 - 20 of 1321

Nancy Shute Powerful antipsychotic medications are being used to treat children and teenagers with ADHD, aggression and behavior problems, a study finds, even though safer treatments are available and should be used first. "There's been concern that these medications have been overused, particularly in young children," says Mark Olfson, a professor of psychiatry at Columbia University who led the study. It was published Wednesday in JAMA Psychiatry. "Guidelines and clinical wisdom suggest that you really should be using a high degree of caution and only using them when other treatments have failed, as a last resort." Olfson and his colleagues looked at prescription data from about 60 percent of the retail pharmacies in the United States in 2006, 2008 and 2010. That included almost 852,000 children, teenagers and young adults. Teens were most likely to be prescribed antipsychotics, with 1.19 percent getting the drugs in 2010, compared to 0.11 percent in younger children. Boys were more likely to be given the medications. Antipsychotic medications like clozapine and olanzapine are used to treat schizophrenia, bipolar disorder and some symptoms of autism. They have not been approved by the Food and Drug Administration to treat aggression and ADHD, but are prescribed off label to reduce disruptive behavior. FDA Debates Safety Of Antipsychotic Drugs In Kids Use of antipsychotics in children has been questioned because the drugs can have serious side effects, including tremors, weight gain, increased diabetes risk and elevated cholesterol. © 2015 NPR

Related chapters from BP7e: Chapter 16: Psychopathology: Biological Basis of Behavior Disorders; Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 12: Psychopathology: Biological Basis of Behavioral Disorders; Chapter 13: Memory, Learning, and Development
Link ID: 21122 - Posted: 07.02.2015

By Erika Beras Marijuana is the drug of choice for people who drink alcohol. And people who use both are twice as likely to do so at the same time than to indulge in just one or the other. That’s according to a study in the journal Alcoholism: Clinical and Experimental Research. [Meenakshi S. Subbaraman and William C. Kerr, Simultaneous Versus Concurrent Use of Alcohol and Cannabis in the National Alcohol Survey The data came from self-reported answers that more than 8,600 people provided to what’s called the National Alcohol Surveys, done by phone in 2005 and 2010. People who used pot and alcohol were about twice as likely to drive drunk than those who just drank. And they doubled their chances of what are referred to as negative social consequences, such as arrests, fights and job problems. Meanwhile, another new study finds that if you’re chronically stoned, you’re more likely to remember things differently from how they happened, or not at all. Researchers showed a series of words to people who do not use marijuana and to regular pot users who had not partaken in a month. A few minutes later, all participants were shown the same list of words along with other words. The volunteers were then asked to identify only the original words. The pot smokers thought more of the new words were in the original list than did the nonusers. And brain scans revealed that the regular pot users showed less activity in brain regions associated with memory and cognitive resources than did the nonusers. The study is in the journal Molecular Psychiatry. [J. Riba et al, Telling true from false: cannabis users show increased susceptibility to false memories] © 2015 Scientific American

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 17: Learning and Memory
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 13: Memory, Learning, and Development
Link ID: 21118 - Posted: 07.02.2015

Patricia Neighmond A report finds mixed results when it comes to how well medical marijuana works to calm pain and control symptoms. And, an editorial says states legalizing pot for medical use may be jumping the gun. DAVID GREENE, HOST: Twenty-three states plus the District of Columbia have approved pot for medical use. But a new study in the Journal of the American Medical Association is raising questions about its safety and effectiveness. Here's NPR's Patti Neighmond. PATTI NEIGHMOND, BYLINE: Researchers from the University of Bristol in the United Kingdom reviewed findings from 79 different studies looking at the effect of marijuana on symptoms ranging from chronic pain to sleep difficulties and mental illness. At best, they found only moderate evidence indicating that marijuana reduced nerve pain and pain from cancer. When it came to other conditions, like nausea and vomiting due to chemotherapy, difficulties sleeping or weight loss among HIV patients, there was some anecdotal evidence suggesting that people may be helped by marijuana, but it was just that - anecdote. D'SOUZA: Which is really the bulk of the evidence that the states have used in approving medical marijuana. NEIGHMOND: In an editorial accompanying this study, Dr. Deepak Cyril D'Souza says states legalizing marijuana for medical use may be jumping the gun before good quality evidence is in. D'SOUZA: If a pharmaceutical company, for example, wanted to get a drug approved for a medical condition and they only submitted anecdotal data, there's absolutely no chance that that drug would be approved. NEIGHMOND: D'Souza is a psychiatrist with Yale University's School of Medicine. For years, he's studied the impact of marijuana on mental health. And the big question, he says, is how routine daily use - the way one might use marijuana to treat a medical condition - affects the body and the brain over the long term. Concerns have been raised about memory loss, panic, paranoia and other severe disorders. © 2015 NPR

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 21089 - Posted: 06.25.2015

By Nicholas Bakalar A new study has found a simple way to significantly reduce teenage smoking: raise the tobacco sales age to 21. In 2005, Needham, Mass., did just that, while surrounding communities kept their age limit at 18. Researchers surveyed 16,000 high school students in Needham and 16 surrounding communities four times between 2006 and 2012, gathering data on their smoking habits. The study is in Tobacco Control. Over the seven years, the number of children under 18 buying cigarettes in Needham decreased to 11.6 percent from 18.4 percent, while in the surrounding communities it hardly changed — down to 19 percent from 19.4. In 2006, 12.9 percent of students in Needham and 14.8 percent of students in surrounding communities reported having smoked in the past 30 days. By 2010, 6.7 percent of Needham students reported smoking, compared with 12 percent in other towns. At the end of the study in 2012, smoking had declined to 5.5 percent in Needham and 8.5 percent outside. “More than 80 percent of smokers begin before 18,” said the lead author, Shari Kessel Schneider, project director at the Education Development Center in Waltham, Mass. “Our findings provide strong support for initiatives going on all across the country to increase the sales age as a means for decreasing youth access to cigarettes, initiation of smoking, and ultimately addiction.” © 2015 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 13: Memory, Learning, and Development
Link ID: 21069 - Posted: 06.18.2015

Almost half of 346,000 deaths from 12 cancers among U.S. adults in one year are attributed to cigarette smoking, despite 50 years of progress on butting out, new research suggests. Cancer researchers updated the estimate on deaths due to cigarette smoking to reflect changes in smoking patterns and how some data now suggest that the risk of cancer death among smokers can increase over time. Of 345,962 cancer deaths in the U.S. in 2011, 167,805 or 48.5 per cent were attributed to smoking cigarettes, Rebecca Siegel and her co-authors said in a research letter published in Monday's issue of JAMA Internal Medicine. The largest proportions of cancer deaths linked to smoking among those 35 and older were for cancers of the lung, bronchus and trachea (125,799 of 156, 855 deaths or 80 per cent) and larynx (2,856 of 3,728 deaths or nearly 77 per cent). About half of the deaths from cancers of the oral cavity, esophagus and urinary bladder were also attributable to smoking. Smoking was also cited as the cause of many deaths from cancer of the colon, kidney, liver, pancreas, stomach, cervix, and from myeloid leukemia. "Cigarette smoking continues to cause numerous deaths from multiple cancers despite half a century of decreasing prevalence," Rebecca Siegel from the American Cancer Society in Atlanta and her co-authors said. Dr. Norman Edelman, a senior scientific advisor to the American Lung Association, said when people hear about smoking and cancer, their thoughts often turn to lung cancer alone. ©2015 CBC/Radio-Canada.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 21057 - Posted: 06.16.2015

By BENEDICT CAREY Marijuana use did not increase among teenagers in the states in which medical marijuana has become legal, researchers reported Monday. The new analysis is the most comprehensive effort to date to answer a much-debated question: Does decriminalization of marijuana lead more adolescents to begin using it? The study found that states that had legalized medical use had higher prevailing rates of teenage marijuana use before enacting the laws, compared with states where the drug remains illegal. Those higher levels were unaffected by the changes in the law, the study found. The report, published in The Lancet Psychiatry, covered a 24-year period and was based on surveys of more than one million adolescents in 48 states. The research says nothing about the effect of legalizing recreational use, however. A primary concern on both sides of the debate over medical marijuana has been that loosening marijuana restrictions might send the wrong message to young people, and make the drug both more available and more appealing. Teenagers who develop and sustain a heavy, daily habit increase their risk of having cognitive difficulties later on, several studies now suggest. Previous research on usage trends in the wake of the laws has been mixed, some reporting evidence of an increase among adolescents and others — including two recent, multistate studies — finding no difference. The new analysis should carry far more weight, experts said, not only because of its size and scope but also because the funders included the National Institute of Drug Abuse, whose director has been outspoken about the risks of increased use. © 2015 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 21056 - Posted: 06.16.2015

By Michael Balter Alcoholic beverages are imbibed in nearly every human society across the world—sometimes, alas, to excess. Although recent evidence suggests that tippling might have deep roots in our primate past, nonhuman primates are only rarely spotted in the act of indulgence. A new study of chimpanzees with easy access to palm wine shows that some drink it enthusiastically, fashioning leaves as makeshift cups with which to lap it up. The findings could provide new insights into why humans evolved a craving for alcohol, with all its pleasures and pains. Scientists first hypothesized an evolutionary advantage to humans’ taste for ethanol about 15 years ago, when a biologist at the University of California, Berkeley, proposed what has come to be called the “drunken monkey hypothesis.” Robert Dudley argued that our primate ancestors got an evolutionary benefit from being able to eat previously unpalatable fruit that had fallen to the ground and started to undergo fermentation. The hypothesis received a boost last year, when a team led by Matthew Carrigan—a biologist at Santa Fe College in Gainesville, Florida—found that the key enzyme that helps us metabolize ethanol underwent an important mutation about 10 million years ago. This genetic change, which occurred in the common ancestor of humans, chimps, and gorillas, made ethanol metabolism some 40 times faster than the process in other primates—such as monkeys—that do not have it. According to the hypothesis, the mutation allowed apes to consume fermented fruit without immediately getting drunk or, worse, succumbing to alcohol poisoning. Nevertheless, researchers had turned up little evidence that primates in the wild regularly eat windfall fruit or are attracted to the ethanol that such fruit contains. Now, a team led by Kimberley Hockings, a primatologist at the Center for Research in Anthropology in Lisbon, concludes from a 17-year study of chimps in West Africa that primates can tolerate significant levels of ethanol and may actually crave it, as humans do. © 2015 American Association for the Advancement of Science

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 6: Evolution of the Brain and Behavior
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 21037 - Posted: 06.10.2015

By Sue Bailey, The Canadian Press Scientific studies increasingly suggest marijuana may not be the risk-free high that teens — and sometimes their parents — think it is, researchers say. Yet pot is still widely perceived by young smokers as relatively harmless, said Dr. Romina Mizrahi, director of the Focus on Youth Psychosis Prevention clinic and research program at the Centre for Addiction and Mental Health. She cites a growing body of research that warns of significantly higher incidence of hallucinations, paranoia and the triggering of psychotic illness in adolescent users who are most predisposed. "When you look at the studies in general, you can safely say that in those that are vulnerable, it doubles the risk." Such fallout is increasingly evident in the 19-bed crisis monitoring unit at the Children's Hospital of Eastern Ontario in Ottawa. "I see more and more cases of substance-induced psychosis," said Dr. Sinthu Suntharalingam, a child and adolescent psychiatrist. "The most common substance that's abused is cannabis." One or two cases a week are now arriving on average. "They will present with active hallucinations," Suntharalingam said. "Parents will be very scared. They don't know what's going on. "They'll be seeing things, hearing things, sometimes they will try to self-harm or go after other people." Potential effects need to be better understood She and Mizrahi, an associate professor in psychiatry at University of Toronto, are among other front-line professionals who say more must be done to help kids understand potential effects. "They know the hard drugs, what they can do," Suntharalingam said. "Acid, they'll tell us it can cause all these things so they stay away from it. But marijuana? They'll be: 'Oh, everybody does it."' Mizrahi said the message isn't getting through. ©2015 CBC/Radio-Canada.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 7: Life-Span Development of the Brain and Behavior
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 13: Memory, Learning, and Development
Link ID: 21025 - Posted: 06.08.2015

By FRANCES ROBLES MIAMI — A hazardous new synthetic drug originating in China is being blamed for 18 recent deaths in a single South Florida county, as police grapple with an inexpensive narcotic that causes exaggerated strength and dangerous paranoid hallucinations. On Thursday, the Fort Lauderdale police killed a man, reportedly high on the man-made street drug, alpha-PVP, known more commonly as flakka, who had held a woman hostage with a knife to her throat. The shooting of Javoris Washington, 29, was the latest in a series of volatile episodes that the police in South Florida have faced with highly aggressive drug users. Law enforcement agencies have had difficulty tamping down a surge in synthetic drugs, which were banned after becoming popular in clubs five years ago only to re-emerge deadlier than ever under new formulations. As soon as legislation catches up with the latest craze, manufacturers design a new drug to take its place, federal and local law enforcement agencies say. In Broward County, which includes Fort Lauderdale and is considered ground zero for the new drug, there have been 18 flakka-related fatalities since September, the chief medical examiner there said. “I have never seen such a rash of cases, all associated with the same substance,” said James N. Hall, an epidemiologist at Nova Southeastern University who has studied the Florida drug market for decades. “It’s probably the worst I have seen since the peak of crack cocaine. Rather than a drug, it’s really a poison.” © 2015 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20974 - Posted: 05.25.2015

by Michael Le Page Humble fungi and a home-brewing kit could soon do what the combined might of the West failed to – halt the thriving poppy industry in Afghanistan, the source of 80 per cent of the world's opium. Genetically engineered yeasts could make it easy to produce opiates such as morphine anywhere, cutting out the international drug smugglers and making such drugs cheap and more readily available. If home-brew drugs become widespread, it would make the Sisyphean nature of stopping the supply of illegal narcotics even more obvious than it is now. "It would be as disruptive to drug enforcement policy as it would be to crime syndicates," says Tanya Bubela, a public health researcher at the University of Alberta in Edmonton, Canada. "It may force the US to rethink its war on drugs." A growing number of drugs, scents and flavours once obtainable only from plants can now be made using genetically modified organisms. Researchers want to add opiates to that list because they are part of a family of molecules that may have useful medicinal properties (see box, below). Plant yields of many of these molecules are vanishingly small, and the chemicals are difficult and expensive to make in the lab. Getting yeast to pump them out would be far cheaper. Yeasts capable of doing this do not exist yet, but none of the researchers that New Scientist spoke to had any doubt that they soon will. "The field is moving much faster than we had previous realised," says John Dueber of the University of California, Berkeley, whose team has just created a yeast that produces the main precursor of opiates. Until recently, Dueber had thought the creation of, say, a morphine-making yeast was 10 years away. He now thinks a low-yielding strain could be made in two or three years.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20951 - Posted: 05.19.2015

Andrew Griffin Evidence that ecigs help people stop smoking real ones is lacking, according to a new analysis. Electronic cigarettes seem to work for the first month, but there isn’t enough evidence to say that they work for longer periods, researchers said. "Until such data are available, there are a number of other smoking cessation aids available that have a more robust evidence base supporting their efficacy and safety,” said lead author of the study Riyad al-Leheb, from the University of Toronto. The analysis looked at four studies of how effective and safe ecigs were, which together had studied 1011 patients. It found that after one month, using ecigs had significantly improved the amount of people that had stopped smoking. But that effect appeared to have gone at three or six months. That included studies on people who had used a placebo against those who had used ecigarettes, as well as those who had used nicotine patches. As well as the apparent lack of permanent help, the analysis found that some studies had found people reported dry cough, throat irritation and shortness of breath. While those adverse effects weren’t any worse among those that used placebo ecigs, they were much less prevalent among those that had used nicotine patches.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20943 - Posted: 05.18.2015

By SABRINA TAVERNISE WASHINGTON — What would make a smoker more likely to quit, a big reward for succeeding or a little penalty for failing? That is what researchers wanted to know when they assigned a large group of CVS employees, their relatives and friends to different smoking cessation programs. The answer offered a surprising insight into human behavior. Many more people agreed to sign up for the reward program, but once they were in it, only a small share actually quit smoking. A far smaller number agreed to risk the penalty, but those who did were twice as likely to quit. The trial, which was described in The New England Journal of Medicine on Wednesday, was the largest yet to test whether offering people financial incentives could lead to better health. It used theories about human decision making that have been developed in psychology and economics departments over several decades and put them into practice with more than 2,500 people who either worked at CVS Caremark, the country’s largest drugstore chain by sales, or were friends or relatives of those employees. Researchers found that offering incentives was far more effective in getting people to stop smoking than the traditional approach of giving free smoking cessation help, such as counseling or nicotine replacement therapy like gum, medication or patches. But they also found that requiring a $150 deposit that would be lost if the person failed to stay off cigarettes for six months nearly doubled the chances of success. “Adding a bit of a stick was much better than a pure carrot,” said Dr. Scott Halpern, deputy director of the Center for Health Incentives and Behavioral Economics at the University of Pennsylvania School of Medicine, who led the study. © 2015 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20925 - Posted: 05.14.2015

Aaron E. Carroll When I was a kid, my parents refused to let me drink coffee because they believed it would “stunt my growth.” It turns out, of course, that this is a myth. Studies have failed, again and again, to show that coffee or caffeine consumption are related to reduced bone mass or how tall people are. Coffee has long had a reputation as being unhealthy. But in almost every single respect that reputation is backward. The potential health benefits are surprisingly large. When I set out to look at the research on coffee and health, I thought I’d see it being associated with some good outcomes and some bad ones, mirroring the contradictory reports you can often find in the news media. This didn’t turn out to be the case. Just last year, a systematic review and meta-analysis of studies looking at long-term consumption of coffee and the risk of cardiovascular disease was published. The researchers found 36 studies involving more than 1,270,000 participants. The combined data showed that those who consumed a moderate amount of coffee, about three to five cups a day, were at the lowest risk for problems. Those who consumed five or more cups a day had no higher risk than those who consumed none. Of course, everything I’m saying here concerns coffee — black coffee. I am not talking about the mostly milk and sugar coffee-based beverages that lots of people consume. These could include, but aren’t limited to, things like a McDonald’s large mocha (500 calories, 17 grams of fat, 72 grams of carbohydrates), a Starbucks Venti White Chocolate Mocha (580 calories, 22 grams of fat, 79 grams of carbs), and a Large Dunkin’ Donuts frozen caramel coffee Coolatta (670 calories, 8 grams of fat, 144 grams of carbs). I won’t even mention the Cold Stone Creamery Gotta-Have-It-Sized Lotta Caramel Latte (1,790 calories, 90 grams of fat, 223 grams of carbs). Regular brewed coffee has 5 or fewer calories and no fat or carbohydrates. © 2015 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20908 - Posted: 05.12.2015

by Clare Wilson IT IS considered a soft drug, but increasing numbers of people are seeking help for cannabis addiction – and there's growing interest in finding ways to treat them. Paradoxically, the most promising treatment may be an extract of cannabis. Last month, researchers at the British Neuroscience Association meeting in Edinburgh, UK, described how the compound, called cannabidiol, helped one person who was severely addicted. A clinical trial is underway. Unlike most forms of drug addiction, there are no medical treatments to help people reduce their cannabis use. "Cannabis dependence is a huge unmet need with no pharmacological treatments," says Tom Freeman of University College London, who is involved in the trial. "It's vital we get one." A possible connection between smoking pot and schizophrenia is fairly well known, but the link is controversial and it affects only a small minority of users. Addiction seems to be a more common problem – yet is often overlooked. There is no universal definition of addiction or dependence. Someone is usually deemed to be addicted to a drug if they want to stop but cannot, or if it has a negative impact on their life. They would probably be experiencing withdrawal symptoms that make it hard to give up. In the case of heavy cannabis use, these can include anxiety and insomnia.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20900 - Posted: 05.08.2015

By ANDREW HIGGINS OSLO — In a country so wary of drug abuse that it limits the sale of aspirin, Pal-Orjan Johansen, a Norwegian researcher, is pushing what would seem a doomed cause: the rehabilitation of LSD. It matters little to him that the psychedelic drug has been banned here and around the world for more than 40 years. Mr. Johansen pitches his effort not as a throwback to the hippie hedonism of the 1960s, but as a battle for human rights and good health. In fact, he also wants to manufacture MDMA and psilocybin, the active ingredients in two other prohibited substances, Ecstasy and so-called magic mushrooms. All of that might seem quixotic at best, if only Mr. Johansen and EmmaSofia, the psychedelics advocacy group he founded with his American-born wife and fellow scientist, Teri Krebs, had not already won some unlikely supporters, including a retired Norwegian Supreme Court judge who serves as their legal adviser. The group, whose name derives from street slang for MDMA and the Greek word for wisdom, stands in the vanguard of a global movement now pushing to revise drug policies set in the 1970s. That it has gained traction in a country so committed to controlling drug use shows how much old orthodoxies have crumbled. The Norwegian group wants not only to stir discussion about prohibited drugs, but also to manufacture them, in part, it argues, to guarantee that they are safe. It recently began an online campaign to raise money so that it can, in cooperation with a Norwegian pharmaceuticals company, start quality-controlled production of psilocybin and MDMA, drugs that Mr. Johansen says saved and transformed his life. © 2015 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20886 - Posted: 05.05.2015

Scott Hensley When patients brought to the ER have uncontrolled blood pressure, neglected asthma or diabetes that hasn't been dealt with, doctors often start treatment right then and there. But what happens when the patient turns out to be addicted to opioids, such as oxycodone or heroin? In case of an overdose, the medical team can take action to rescue the patient. The underlying addiction is something else, though. Like asthma or diabetes, opioid addiction is a chronic condition. Could starting treatment for addiction in the ER get someone on right road faster? Doctors at Yale University thought it was possible. "You can normalize this chronic disease like any other chronic disease," says Dr. Gail D'Onofrio, chief of emergency medicine at Yale's med school. A kit with naloxone, also known by its brand name Narcan, is displayed at the South Jersey AIDS Alliance in Atlantic City. Naloxone counters an overdose with heroin or certain prescription painkillers by blocking the receptors these opioids bind to in the brain. She and her colleagues at Yale-New Haven Hospital in Connecticut tested whether prescribing medicine to ease withdrawal symptoms in combination with a brief counseling intervention and a focused referral for help would improve the chances a person would get into addiction treatment. It worked pretty well, according to results of a study published Tuesday in JAMA, the journal of the American Medical Association. © 2015 NPR

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20862 - Posted: 04.30.2015

By ALAN SCHWARZ A sharp rise in visits to emergency rooms and calls to poison control centers nationwide has some health officials fearing that more potent and dangerous variations of a popular drug known as spice have reached the nation’s streets, resulting in several deaths. In the first three weeks of April, state poison control centers received about 1,000 reports of adverse reactions to spice — the street name for a family of synthetic substances that mimic the effects of marijuana — more than doubling the total from January through March, according to the American Association of Poison Control Centers. The cases, which can involve spice alone or in combination with other substances, have appeared four times as often this year as in 2014, the organization said. On Thursday alone there were 172 reports, by far the most in one day this year. Health departments in Alabama, Mississippi and New York have issued alerts this month about more spice users being rushed to hospitals experiencing extreme anxiety, violent behavior and delusions, with some of the cases resulting in death. Similar increases have occurred in Arizona, Florida, New Jersey and Texas. The total number of fatalities nationwide this year is not available, health officials said. One person in Louisiana died Wednesday and two others were in intensive care, said Mark Ryan, the director of the Louisiana Poison Center. “We had one hospital in the Baton Rouge area that saw over 110 cases in February. That’s a huge spike,” Dr. Ryan said. “There’s a large amount of use going on. When one of these new ingredients — something that’s more potent and gives a bigger high — is released and gets into distribution, it can cause these more extreme effects.” © 2015 The New York Times Compan

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20848 - Posted: 04.25.2015

By ALAN SCHWARZ Fading fast at 11 p.m., Elizabeth texted her dealer and waited just 30 minutes for him to reach her third-floor New York apartment. She handed him a wad of twenties and fifties, received a tattered envelope of pills, and returned to her computer. Her PowerPoint needed another four hours. Investors in her health-technology start-up wanted re-crunched numbers, a presentation begged for bullet points and emails from global developers would keep arriving well past midnight. She gulped down one pill — pale orange, like baby aspirin — and then, reconsidering, took one of the pinks, too. “O.K., now I can work,” Elizabeth exhaled. Several minutes later, she felt her brain snap to attention. She pushed her glasses up her nose and churned until 7 a.m. Only then did she sleep for 90 minutes, before arriving at her office at 9. The pills were versions of the drug Adderall, an amphetamine-based stimulant prescribed for attention deficit hyperactivity disorder that many college students have long used illicitly while studying. Now, experts say, stimulant abuse is graduating into the work force. But in interviews, dozens of people in a wide spectrum of professions said they and co-workers misused stimulants like Adderall, Vyvanse and Concerta to improve work performance. Most spoke on the condition of anonymity for fear of losing their jobs or access to the medication. Doctors and medical ethicists expressed concern for misusers’ health, as stimulants can cause anxiety, addiction and hallucinations when taken in high doses. But they also worried about added pressure in the workplace — where the use by some pressures more to join the trend. © 2015 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 18: Attention and Higher Cognition
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology; Chapter 14: Attention and Consciousness
Link ID: 20821 - Posted: 04.20.2015

By SABRINA TAVERNISE E-cigarettes have arrived in the life of the American teenager. Use of the devices among middle- and high school students tripled from 2013 to 2014, according to federal data released on Thursday, bringing the share of high school students who use them to 13 percent — more than smoke traditional cigarettes. About a quarter of all high school students and 8 percent of middle school students — 4.6 million young people altogether — used tobacco in some form last year. The sharp rise of e-cigarettes, together with a substantial increase in the use of hookah pipes, led to 400,000 additional young people using a tobacco product in 2014, the first increase in years, though researchers pointed out the percentage of the rise fell within the report’s margin of error. But the report also told another story. From 2011 to 2014, the share of high school students who smoked traditional cigarettes declined substantially, to 9 percent from 16 percent, and use of cigars and pipes ebbed too. The shift suggested that some teenage smokers may be using e-cigarettes to quit. Smoking is still the single-biggest cause of preventable death in the United States, killing more than 480,000 Americans a year, and most scientists agree that e-cigarettes, which deliver the nicotine but not the dangerous tar and other chemicals, are likely to be far less harmful than traditional cigarettes. The numbers came as a surprise and seemed to put policy makers into uncharted territory. The Food and Drug Administration took its first tentative step toward regulating e-cigarettes last year, but the process is slow, and many experts worry that habits are forming far faster than rules are being written. Because e-cigarettes are so new, scientists are still gathering evidence on their long-term health effects, leaving regulators scrambling to gather data. © 2015 The New York Times Company

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20811 - Posted: 04.18.2015

By Laura Sanders To drive a rat to drink, make it smoke first. Rats dependent on nicotine escalate their drinking more quickly than rats that haven’t been exposed to nicotine, researchers report in the April 15 Journal of Neuroscience. The results help explain why alcohol and tobacco addictions in people often go hand in hand. After nicotine injections, rats that had previously been exposed to alcohol dosed themselves with more alcohol than rats unexposed to nicotine did. Scientists were able to curb this booziness: Rats injected with a compound that made brain cells ignore nicotine did not boost their intake of alcohol. The double whammy of nicotine and alcohol dependence may be due to a select group of nerve cells throughout the rat brain that respond to this nicotine-aided drinking, Olivier George of the Scripps Research Institute in La Jolla, Calif., and colleagues found. If a similar response happens in humans, studying these particular nerve cells might ultimately lead to better ways to curb both alcohol and tobacco dependencies, the researchers write. R. Leão et al. Chronic nicotine activates stress/reward-related brain regions and facilitates the transition to compulsive alcohol drinking. Journal of Neuroscience. Vol. 35, April 15, 2015. doi:10.1523/JNEUROSCI.3302-14.2015. © Society for Science & the Public 2000 - 2015.

Related chapters from BP7e: Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Related chapters from MM:Chapter 4: The Chemistry of Behavior: Neurotransmitters and Neuropharmacology
Link ID: 20799 - Posted: 04.15.2015